



Asia Pacific Consortium of Gene and Cell Therapy 2019

2019.11.07 - 08, Seoul, Korea

Introduction

Our major mission is to become a truly international society, which can facilitate and accelerate commercialization of innovative biotherapeutics. To achieve our primary objective, this year's Asia Pacific Consortium of Gene and Cell Therapy (APCGCT) brings together leading experts of gene and cell therapy from industrial, clinician, academic, and drug regulatory backgrounds. The main focus of the Society is to foster camaraderie and scientific collaboration among several entities that are integral to bringing innovative therapeutic solutions to patients worldwide.

- 행 사 명 - Asia Pacific Consortium of Gene and Cell Therapy 2019
- 일 시 - 2019. 11. 07 – 08
- 장 소 - 한양대학교 HIT(Hanyang Institute of Technology) center (Building No.701)
- 웹사이트 - <http://apcgct2019.com>

Registration

- E- mail - apcgct2019@apcgct2019.com
- 사전등록 마감일 – OCT 20, 2019

사전등록 마감일은 10월 20일 까지이며, 사전 등록 시에만 Program book이 제공됩니다.
사전등록을 원하시면 사전 등록 신청서를 작성하시어 메일 주십시오.

Abstract Submission

- E- mail - apcgct2019@apcgct2019.com
- 초록접수 마감일 – SEP 30, 2019

Poster award 가 있을 예정입니다. 대상 (약 30 만원 상당, 1명), 최우수상 (20만원 상당, 2명), 우수상(10만원 상당, 3명)의 시상이 있을 예정이오니 많은 분들의 적극적인 참여를 부탁드립니다.

Contact Information

- 심포지움 사무국
- E- mail - apcgct2019@apcgct2019.com (+82-2-2220-4853~4)

Invitation

Currently 15 types of gene therapeutics that have been commercialized throughout the world. Further, recent clinical breakthrough and remarkable therapeutic benefits of CAR-T therapies forecast that gene and cell therapeutics will continue to be of great importance for cancer therapy of the present and the future. We believe that 2019 will be a year to build on this remarkable upward trajectory and take another step forward to improve patient outcomes.

We cordially invite you to participate in the Annual Meeting of the Asia Pacific Consortium of Gene and Cell Therapy (APCGCT) in Seoul over November 7-8th, 2019 to further accelerate and improve biopharmaceutical development process.

In accordance with rapid transformation in the biotherapeutic market, annual conference of APCGCT aims to provide most up-to-date information and development within the field of gene and cell therapy that accurately represents the evolving market this year. APCGCT 2019 is the first symposium to be held in Korea, which brings together about 25 world-renown experts and scholars from diverse backgrounds (academia, drug regulatory body, clinic, and pharmaceutical industry). Experts will provide innovative presentation and vibrant discussion on current trend of research, development in translation research, recent clinical trial results, and commercialization process of gene and cell therapeutics.

Ultimately, we firmly believe that APCGCT2019 can serve as a rendezvous point for leading experts from diverse backgrounds to exchange innovative ideas and forge strong and beneficial partnerships to exponentially expedite commercialization of promising gene and cell therapeutics.

With all our colleagues and friends from the APCGCT board, we sincerely wish you will partake in an exciting and productive meeting.

Invited Speakers

Speaker	Abstract title
Keisuke Nimura	Elucidating a mechanism for RNA splicing driving human prostate cancer progression
Yaohe Wang	New strategies of improving intravenous delivery of oncolytic vaccinia virus for cancer treatment
Won-jong Kim	Drug-loaded polymeric nanoparticles for gene and cell therapy
Robert M. Frederickson	Molecular Therapy in Asia: challenges and opportunities
Min Liang	Novel oncolytic vaccinia virus which expressing anti-PD1 and anti-CD137 Monoclonal Antibodies and its anti-cancer effect
Masatoshi Tagawa	An Intrapleural Administration of Adenoviruses Expressing NK4 Gene to Inhibit the HGF/c-Met Signal Pathway Produced Minimal Adverse Events in a Phase I Clinical Study Targeted for Mesothelioma
Wenlin Huang	Molecular mechanism of new targeting is explored in colon rectal carcinoma
Tomoki Todo	Clinical development of oncolytic herpes virus G47Δ
Hideki Kasuya	Antitumor predictive factors associated with oncolytic virus C-REV (formaly HF10
Farzin Farzaneh	Cells, genes and peptides for active immune therapy of cancer
Ryuichi Morishita	Collategen, HGF Plasmid DNA, as First Approved Gene Therapy Drug to Treat Cardiovascular Diseases
Byung-Geon Rhee	Allogenic Single Cell derived Clonal Mesenchymal Stem Cell's Clinical Application
Hironori Nakagami	Therapeutic Vaccines for Hypertension and life style related diseases
Sae-Won Kim	Discovery of a novel NK cell platform for adoptive cancer immunotherapy with chimeric antigen receptors
Xiao-Song Zhong	Relapsed/Refractory Cancer Patients were Treated With Tumor-Specific T Cells
Sungwan Kim	Polymeric Gene Delivery Systems – Recent Progress
Sa-Won Lee	Polymeric micelle-based nanomedicines for treatment of cancer
Sang-su Bae	Genome editing using CRISPR and its therapeutic application
Xiawei Wei	The cationic nanocarriers and their roles in the immune regulation
Xin Tan	PI3K/AKT-mediated Upregulation of WDR5 Promotes Colorectal Cancer Metastasis by Directly Targeting ZNF407
Zhe Zhang	A personalised iPSC-derived whole tumor cell vaccine evokes effective immunoreaction for prevention of lung cancer development
Shuangshuang Lu	A Virus-Infected, Reprogrammed Somatic cell-derived Tumor cell (VIReST) regime can prevent initiation and progression of pancreatic cancer
Takafumi Nakamura	Next-generation oncolytic vaccinia virus vectors for cancer virotherapy
Jin -Ho Choy	10B-molecular bomb entrained 2D nanostealth targets tumor cells and tissues needing boron neutron capture therapy (BNCT)
Paola Grandi	CG0070, an Oncolytic Adenovirus, for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): 12 Month Follow-Up from A Multicenter Phase II Trial